Association between Cutaneous Nevi and Breast Cancer in the Nurses' Health Study: A Prospective Cohort Study

English version České info

Background:
Cutaneous nevi are suggested to be hormone-related. We hypothesized that the number of cutaneous nevi might be a phenotypic marker of plasma hormone levels and predict subsequent breast cancer risk.

Methods and Findings:
We followed 74,523 female nurses for 24 y (1986–2010) in the Nurses' Health Study and estimate the relative risk of breast cancer according to the number of cutaneous nevi. We adjusted for the known breast cancer risk factors in the models. During follow-up, a total of 5,483 invasive breast cancer cases were diagnosed. Compared to women with no nevi, women with more cutaneous nevi had higher risks of breast cancer (multivariable-adjusted hazard ratio, 1.04, 95% confidence interval [CI], 0.98–1.10 for 1–5 nevi; 1.15, 95% CI, 1.00–1.31 for 6–14 nevi, and 1.35, 95% CI, 1.04–1.74 for 15 or more nevi; p for continuous trend = 0.003). Over 24 y of follow-up, the absolute risk of developing breast cancer increased from 8.48% for women without cutaneous nevi to 8.82% (95% CI, 8.31%–9.33%) for women with 1–5 nevi, 9.75% (95% CI, 8.48%–11.11%) for women with 6–14 nevi, and 11.4% (95% CI, 8.82%–14.76%) for women with 15 or more nevi. The number of cutaneous nevi was associated with increased risk of breast cancer only among estrogen receptor (ER)–positive tumors (multivariable-adjusted hazard ratio per five nevi, 1.09, 95% CI, 1.02–1.16 for ER+/progesterone receptor [PR]–positive tumors; 1.08, 95% CI, 0.94–1.24 for ER+/PR− tumors; and 0.99, 95% CI, 0.86–1.15 for ER−/PR− tumors). Additionally, we tested plasma hormone levels according to the number of cutaneous nevi among a subgroup of postmenopausal women without postmenopausal hormone use (n = 611). Postmenopausal women with six or more nevi had a 45.5% higher level of free estradiol and a 47.4% higher level of free testosterone compared to those with no nevi (p for trend = 0.001 for both). Among a subgroup of 362 breast cancer cases and 611 matched controls with plasma hormone measurements, the multivariable-adjusted odds ratio for every five nevi attenuated from 1.25 (95% CI, 0.89–1.74) to 1.16 (95% CI, 0.83–1.64) after adjusting for plasma hormone levels. Key limitations in this study are that cutaneous nevi were self-counted in our cohort and that the study was conducted in white individuals, and thus the findings do not necessarily apply to other populations.

Conclusions:
Our results suggest that the number of cutaneous nevi may reflect plasma hormone levels and predict breast cancer risk independently of previously known factors.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association between Cutaneous Nevi and Breast Cancer in the Nurses' Health Study: A Prospective Cohort Study. PLoS Med 11(6): e32767. doi:10.1371/journal.pmed.1001659
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001659

Souhrn

Zdroje

1. ArmstrongK, EisenA, WeberB (2000) Assessing the risk of breast cancer. N Engl J Med 342: 564–571.

2. HarrisJR, LippmanME, VeronesiU, WillettW (1992) Breast cancer (1). N Engl J Med 327: 319–328.

3. KeyT, ApplebyP, BarnesI, ReevesG (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606–616.

4. ZhangX, TworogerSS, EliassenAH, HankinsonSE (2013) Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137: 883–892.

5. KaaksR, BerrinoF, KeyT, RinaldiS, DossusL, et al. (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97: 755–765.

6. DriscollMS, Grant-KelsJM (2009) Nevi and melanoma in the pregnant woman. Clin Dermatol 27: 116–121.

7. DriscollMS, Grant-KelsJM (2007) Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 57: 919–931.

8. NanH, XuM, KraftP, QureshiAA, ChenC, et al. (2011) Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 20: 3718–3724.

9. FearsTR, BirdCC, GuerryD4th, SagebielRW, GailMH, et al. (2002) Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res 62: 3992–3996.

10. ZhangM, SongF, LiangL, NanH, ZhangJ, et al. (2013) Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. Hum Mol Genet 22: 2948–2959.

11. HankinsonSE, WillettWC, MansonJE, ColditzGA, HunterDJ, et al. (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292–1299.

12. MissmerSA, EliassenAH, BarbieriRL, HankinsonSE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96: 1856–1865.

13. SodergardR, BackstromT, ShanbhagV, CarstensenH (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem Mol Biol 16: 801–810.

14. HallPF (1969) The influence of hormones on melanogenesis. Australas J Dermatol 10: 125–139.

15. ZouboulisCC, ChenWC, ThorntonMJ, QinK, RosenfieldR (2007) Sexual hormones in human skin. Horm Metab Res 39: 85–95.

16. EliassenAH, HankinsonSE (2008) Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 630: 148–165.

17. LiaoDJ, DicksonRB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80: 175–189.

18. SiiteriPK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45: 277–282.

19. ClarkeCA, PurdieDM, GlaserSL (2006) Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer 6: 170.

20. EnglishDR, ArmstrongBK (1994) Melanocytic nevi in children. II. Observer variation in counting nevi. Am J Epidemiol 139: 402–407.

21. GallusS, NaldiL, CarliP, La VecchiaC (2007) Italian Group for Epidemiologic Research in Dermatology (2007) Nevus count on specific anatomic sites as a predictor of total body count: a survey of 3,406 children from Italy. Am J Epidemiol 166: 472–478.

22. ChoE, RosnerBA, FeskanichD, ColditzGA (2005) Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 23: 2669–2675.

23. NanH, XuM, ZhangJ, ZhangM, KraftP, et al. (2011) Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Hum Mol Genet 20: 2673–2679.